story of the week
Neoantigen Therapy Plus Anti–PD-1 in Patients With Advanced Melanoma, NSCLC, or Bladder Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cell
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients With Advanced Melanoma, Non-Small Cell Lung Cancer, or Bladder Cancer
Cell 2020 Oct 15;183(2)347-362.e24, PA Ott, S Hu-Lieskovan, B Chmielowski, R Govindan, A Naing, N Bhardwaj, K Margolin, MM Awad, MD Hellmann, JJ Lin, T Friedlander, ME Bushway, KN Balogh, TE Sciuto, V Kohler, SJ Turnbull, R Besada, RR Curran, B Trapp, J Scherer, A Poran, D Harjanto, D Barthelme, YS Ting, JZ Dong, Y Ware, Y Huang, Z Huang, A Wanamaker, LD Cleary, MA Moles, K Manson, J Greshock, ZS Khondker, E Fritsch, MS Rooney, M DeMario, RB Gaynor, L SrinivasanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.